Skip to main content

Advertisement

SpringerLink
Log in

In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Staphylococci are a leading cause of skin and soft tissue infections (SSTIs) and bacteremia in France, a country with a high prevalence of oxacillin resistance. We evaluated the in vitro activity of daptomycin compared with reference compounds against 445 Staphylococcus aureus and 53 coagulase-negative Staphylococci (CNS) collected during two large nationwide studies performed in 2006 and 2007. The percentage of oxacillin resistance among S. aureus was 13.6% (SSTIs) and 30.7% (bacteremia). Daptomycin showed lower MIC90 levels compared to vancomycin, teicoplanin, and linezolid (0.19 mg/L vs. 2, 1.5, and 1 mg/L, respectively), irrespective of oxacillin susceptibility. Amongst the CNS, 64.2% of the isolates originated from clinical bacteremia were resistant to oxacillin and 24.5% to teicoplanin; all but one Staphylococci were susceptible to daptomycin (MIC = 1.5 mg/l). As with linezolid, daptomycin seems to constitute an alternative option to treat some staphylococcal infections in the French context of high oxacillin resistance prevalence and high glycopeptides MIC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Moet GJ, Jones RN, Biedenbach DJ et al (2007) Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis 57:7–13. doi:10.1016/j.diagmicrobio.2006.05.009

    Article  PubMed  Google Scholar 

  2. Decousser JW, Pina P, Picot F et al (2003) Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother 51:1213–1222. doi:10.1093/jac/dkg201

    Article  PubMed  CAS  Google Scholar 

  3. Decousser JW, Pina P, Viguier F et al (2004) Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002. Antimicrob Agents Chemother 48:3636–3639. doi:10.1128/AAC.48.9.3636-3639.2004

    Article  PubMed  CAS  Google Scholar 

  4. Galas M, Decousser JW, Breton N et al (2008) Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-β-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother 52:786–789. doi:10.1128/AAC.00906-07

    Article  PubMed  CAS  Google Scholar 

  5. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical breakpoints. Available online at: http://www.srga.org/eucastwt/MICTAB/index.html

  6. French Society of Microbiology (CASFM) Guidelines of the Antimicrobial Committee of the French Society of Microbiology. Available online at: http://www.sfm.asso.fr/nouv/general.php?pa=2

  7. Lina G, Piémont Y, Godail-Gamot F et al (1999) Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29:1128–1132. doi:10.1086/313461

    Article  PubMed  CAS  Google Scholar 

  8. Kollef MH (2007) Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 45(Suppl 3):S191–S195. doi:10.1086/519470

    Article  PubMed  CAS  Google Scholar 

  9. Lodise TP, Graves J, Evans A et al (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320. doi:10.1128/AAC.00113-08

    Article  PubMed  CAS  Google Scholar 

  10. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:1330–1336

    Article  PubMed  CAS  Google Scholar 

  11. European Antimicrobial Resistance Surveillance System (EARSS) Home page at: http://www.rivm.nl/earss

  12. Vandenesch F, Naimi T, Enright MC et al (2003) Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 9:978–984

    PubMed  Google Scholar 

  13. Daum RS (2007) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357:380–390. doi:10.1056/NEJMcp070747

    Article  PubMed  CAS  Google Scholar 

  14. Jorgensen JH, Crawford SA (2006) Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 44:2126–2129. doi:10.1128/JCM.00076-06

    Article  PubMed  CAS  Google Scholar 

  15. Jevitt LA, Thorne GM, Traczewski MM et al (2006) Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 44:3098–3104. doi:10.1128/JCM.00665-06

    Article  PubMed  CAS  Google Scholar 

  16. Streit JM, Jones RN, Sader HS (2004) Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 53:669–674. doi:10.1093/jac/dkh143

    Article  PubMed  CAS  Google Scholar 

  17. Sader HS, Streit JM, Fritsche TR et al (2006) Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002–2004). Clin Microbiol Infect 12:844–852. doi:10.1111/j.1469-0691.2006.01550.x

    Article  PubMed  CAS  Google Scholar 

  18. Sader HS, Watters AA, Fritsche TR et al (2007) Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 7:29. doi:10.1186/1471-2334-7-29

    Article  PubMed  Google Scholar 

  19. Critchley IA, Draghi DC, Sahm DF et al (2003) Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 51:639–649. doi:10.1093/jac/dkg130

    Article  PubMed  CAS  Google Scholar 

  20. Leonard SN, Cheung CM, Rybak MJ (2008) Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52:2974–2976. doi:10.1128/AAC.00257-08

    Article  PubMed  CAS  Google Scholar 

  21. Fluit AC, Schmitz FJ, Verhoef J et al (2004) In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 48:1007–1011. doi:10.1128/AAC.48.3.1007-1011.2004

    Article  PubMed  CAS  Google Scholar 

  22. Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666–674. doi:10.1056/NEJMoa055356

    Article  PubMed  CAS  Google Scholar 

  23. Grayson ML (2007) The treatment triangle for staphylococcal infections. N Engl J Med 355:724–727. doi:10.1056/NEJMe068152

    Article  Google Scholar 

  24. Tenover FC, Moellering RC (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208–1215. doi:10.1086/513203

    Article  PubMed  CAS  Google Scholar 

  25. Cosgrove SE, Fowler VG Jr (2008) Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46(Suppl 5):S386–S393. doi:10.1086/533595

    Article  PubMed  CAS  Google Scholar 

  26. Micek ST (2007) Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 45(Suppl 3):S184–S190. doi:10.1086/519471

    Article  PubMed  CAS  Google Scholar 

  27. Ben Mansour EH, Jacob E, Monchi M et al (2003) Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 22:372–373. doi:10.1007/s10096-003-0959-6

    Article  PubMed  CAS  Google Scholar 

  28. Naber CK (2008) Future strategies for treating Staphylococcus aureus bloodstream infections. Clin Microbiol Infect 14(Suppl 2):26–34

    PubMed  CAS  Google Scholar 

  29. Boucher HW, Sakoulas G (2007) Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45:601–608. doi:10.1086/520655

    Article  PubMed  CAS  Google Scholar 

  30. Small PM, Chambers HF (1990) Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227–1231

    PubMed  CAS  Google Scholar 

  31. Jones RN, Fritsche TR, Sader HS et al (2007) Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 59:199–209. doi:10.1016/j.diagmicrobio.2007.06.001

    Article  PubMed  CAS  Google Scholar 

  32. Weigelt J, Itani K, Stevens D et al (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49:2260–2266. doi:10.1128/AAC.49.6.2260-2266.2005

    Article  PubMed  CAS  Google Scholar 

  33. Stevens DL, Herr D, Lampiris H et al (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481–1490. doi:10.1086/340353

    Article  PubMed  CAS  Google Scholar 

  34. Birmingham MC, Rayner CR, Meagher AK et al (2003) Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159–168. doi:10.1086/345744

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was partially funded by a grant from Novartis, France.

The ColBVH study group participants are: Drs. ALBA SAUVIAT C, AUVRAY C, BARTIZEL C, BAUDINAT I, BENABID E, BENSEDDIK Z, BESSIS F, BIESSY H, BIETRIX M, BLANC V, BLAND S, BOUCAUD MY, BOUQUIGNY C, BRISOU P, CAILLEAUX V, CANCET B, CARTIER-RIVIERE B, CATTIER B, CECILLE A, CHAMBREUIL G, CHAPLAIN C, CHARDON H, CHIOUKH N, COLLOT E, CREPET F, DE MONTCLOS H, DELARBRE J, ESTEVE V, GRAVET A, DELIGNE D, DEMACHY MC, DOAT V, DUBOURDIEU B, DUBOURDIEU S, DURAND C, EL HARRIF-HERAUD, EVREUX F, FONSALE N, GABRIEL S, GAVIGNET M, GEFFROY F, GRAVET A, GRISE G, GUIET P, HERMES I, HEURTE J, HEUSSE E, JACOB JL, MENOUNI O, RIGAL C, JAN D, JAOUEN E, KHATIB G, LAFARGUE JP, LAMARCIA R, LAMY B, LAURENS E, LEBRUN C, LE COUSTUMIER, LECAILLON E, LEMBLE C, LEOTARD S, LETOUZEY MN, MANDJEE A, MANGEOL A, MARMONIER A, MARTIN R, MENOUAR M, MENOUNI ODILE V, MICHEL A, NERI D, NOULARD MJ, PALETTE X, PANGON B, PAYEN C, PIERREJEAN D, POLLET J, PORCHERET H, POSSON M, RAOULT A, RICHARDIN F, RIGAL C, SABOT O, SAMAILLE S, SANCHEZ R, SCAT Y, SECHER A, SIMEON D, THELLIER JP, TOURRANS B, VACHEE A, VASSEUR, VERDIER I, VERHAEGHE A, VILLEMAIN M, VILLENEUVE L.

Author information

Authors and Affiliations

  1. Department of Biology and Infection Control, Centre Hospitalier de Dourdan, 91415, Dourdan, France

    O. Gallon

  2. Department of Microbiology and Infection Control, AP-HP, Centre Hospitalo-Universitaire Antoine Béclère, 92140, Clamart, France

    C. Guillet-Caruba, F. Doucet-Populaire & J.-W. Decousser

  3. Department of Biology, Centre Hospitalier du Bassin de Thau, 34200, Sète, France

    B. Lamy

  4. Centre National de Référence des Staphylocoques, Faculté Laennec, INSERM 851, 69372, Lyon, France

    F. Laurent

  5. Department of Bacteriology, Hôpital de la Croix Rousse, 69317, Lyon, France

    F. Laurent

  6. Department of Microbiology, EA 4065, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Paris, France

    F. Doucet-Populaire

Authors
  1. O. Gallon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Guillet-Caruba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Lamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Laurent
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Doucet-Populaire
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J.-W. Decousser
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Collège de Bactériologie Virologie Hygiène Study Group (ColBVH)

Corresponding author

Correspondence to J.-W. Decousser.

Additional information

The ColBVH study group participants are listed in the Acknowledgments

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallon, O., Guillet-Caruba, C., Lamy, B. et al. In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies. Eur J Clin Microbiol Infect Dis 28, 1209–1215 (2009). https://doi.org/10.1007/s10096-009-0764-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-009-0764-y

Keywords

Search

Navigation